HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.